Angioedema News

April 12, 2021April 12, 2021

Life Quality Gains Evident With Newer Preventive HAE Therapies, Survey Finds

Angioedema News

Newer preventive therapies for hereditary angioedema (HAE) lead to a better quality of life and fewer attacks than on-demand treatments, according to a large patient survey study. The study, “Assessing ... Read more

April 8, 2021April 8, 2021

Takhzyro Found More Effective Than Cinryze at Preventing HAE Attacks

Angioedema News

Takhzyro (lanadelumab) is more effective than Cinryze at preventing swelling attacks in people with hereditary angioedema (HAE), a new study indicates. Analyses suggested that treatment with Takhzyro reduced the rates ... Read more

April 5, 2021April 5, 2021

Ionis’ HAE Therapy Greatly Reduced Monthly Swelling Attacks During Trial

Angioedema News

The experimental therapy IONIS-PKK-LRx can significantly lower the number of monthly swelling attacks in patients with hereditary angioedema (HAE) type 1 and 2, according to top-line data from an ongoing ... Read more

April 1, 2021April 1, 2021

Cost of Rare Diseases in US? Nearly $1 Trillion in 2019, EveryLife Foundation Finds

Angioedema News

As anyone affected by a rare disease knows, treating the illness while trying to go about everyday life is an expensive undertaking.  But exactly how expensive — in terms of ... Read more

March 26, 2021March 30, 2021

Haegarda Available for Eligible Patients in Canada Starting April 6

Angioedema News

Haegarda, CSL Behring’s preventive treatment for hereditary angioedema (HAE) attacks, will be available to eligible HAE patients across Canada starting on April 6. The availability announcement was issued by Canadian ... Read more

March 25, 2021March 26, 2021

Off-label C1 Inhibitor Concentrate May Be Effective in ACEI-induced Acute Angioedema

Angioedema News

Off-label C1 inhibitor concentrate successfully treated people with severe acute angioedema triggered by the use of so-called ACE inhibitor medications, a small study has found. The study, “Effectiveness of C1-INH ... Read more

March 22, 2021March 22, 2021

Intellia Seeks to Advance Its Gene-editing Therapy to Human Trials

Angioedema News

Intellia Therapeutics is advancing clinical manufacturing activities to support its plans to file regulatory applications for first-in-human clinical trials of NTLA-2002, its experimental gene-editing therapy for hereditary angioedema (HAE). The submissions ... Read more

March 18, 2021March 18, 2021

Orladeyo Now Available in France Via Early Access Program

Angioedema News

Orladeyo (berotralstat) — an oral therapy developed by BioCryst Pharmaceuticals to prevent swelling attacks in people with hereditary angioedema (HAE) — is now available to patients, 12 and older, in ... Read more

March 15, 2021March 16, 2021

Takeda Seeks Approval in Japan of Takhzyro to Prevent Swelling Attacks

Angioedema News

Takeda has submitted an application in Japan seeking regulatory approval of Takhzyro (lanadelumab) for the treatment of hereditary angioedema (HAE). The company’s new drug application to the Japanese Ministry of ... Read more

March 11, 2021March 11, 2021

First Patient Dosed in Phase 2 Trial Testing PHVS416 for HAE Attacks

Angioedema News

The first patient has been dosed in RAPIDe-1, a Phase 2 trial of PHVS416, an oral on-demand treatment being developed by Pharvaris for swelling attacks in people with hereditary angioedema ... Read more

March 8, 2021March 8, 2021

Pink, Green, Blue and Purple Lights Illuminated World for Rare Disease Day

Angioedema News, COVID-19 News

Many diseases have their own awareness color — breast cancer is pink, muscular dystrophy is green, and AIDS is red, for example — but what’s the significance of pink, green, ... Read more

March 8, 2021March 8, 2021

BioCryst Seeks UK Approval of Orladeyo for Preventing HAE Attacks

Angioedema News

BioCryst Pharmaceuticals is seeking the approval of Orladeyo (berotralstat) in the United Kingdom as a preventive treatment for sudden and recurrent swelling attacks in people with hereditary angioedema (HAE), ages ... Read more

March 5, 2021March 6, 2021

Long-term Haegarda Found to Improve Quality of Life in HAE Patients

Angioedema News

Long-term treatment with the approved therapy Haegarda leads to improved quality of life in people with type 1 or 2 hereditary angioedema (HAE), new clinical trial data show. The findings ... Read more

March 1, 2021March 1, 2021

Orladeyo Recommended in EU as 1st Oral Treatment to Prevent HAE Attacks

Angioedema News

BioCryst Pharmaceuticals’ Orladeyo (berotralstat) has been recommended for approval in the European Union as the first oral therapy for preventing swelling attacks in people with hereditary angioedema (HAE), ages 12 ... Read more

February 26, 2021February 26, 2021

Single PHA121 Dose Can Block Bradykinin Effects in Healthy Volunteers

Angioedema News

A single dose of PHA121 (PHA-022121), Pharvaris’ investigational therapy for hereditary angioedema (HAE), is safe and can rapidly and sustainably block bradykinin-induced changes in blood parameters, according to two studies ... Read more